Are virus-induced cancers more sensitive to checkpoint inhibitors?

Future Oncol. 2016 Dec;12(23):2665-2668. doi: 10.2217/fon-2016-0283. Epub 2016 Aug 11.
No abstract available

Keywords: HIV; HPV; cervical cancer; head and neck cancer; immune checkpoint inhibitors; ipilimumab; mutational load; nivolumab; pembrolizumab; virus-induced cancers.

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • B7-H1 Antigen / antagonists & inhibitors*
  • CTLA-4 Antigen / antagonists & inhibitors
  • Cell Transformation, Viral*
  • Clinical Trials as Topic
  • Humans
  • Molecular Targeted Therapy*
  • Neoplasms / drug therapy*
  • Neoplasms / etiology*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • B7-H1 Antigen
  • CTLA-4 Antigen
  • Programmed Cell Death 1 Receptor